Fate Therapeutics, Inc. (FATE) Financials
FATE Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 506.2 million | 137.8 million |
2023-09-30 | 543.8 million | 141.0 million |
2023-06-30 | 584.8 million | 147.0 million |
2023-03-31 | 630.3 million | 152.9 million |
FATE Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -36.8 million | 9.5 million |
2023-09-30 | -38.8 million | 10.1 million |
2023-06-30 | -30.7 million | 12.9 million |
2023-03-31 | -32.1 million | 11.0 million |
FATE Net Income
No data available :(
FATE Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 315.2 million | - | 103.5 million |
2023-09-30 | 349.7 million | - | 105.0 million |
2023-06-30 | 377.9 million | - | 106.3 million |
2023-03-31 | 408.9 million | - | 107.6 million |
FATE Shares Outstanding
FATE Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 181000 | 26.9 million | 17.9 million | - |
2023-09-30 | 565000 | 34.3 million | 18.9 million | - |
2023-06-30 | 2.2 million | 40.9 million | 22.6 million | - |
2023-03-31 | 3.2 million | 65.6 million | 21.9 million | - |
FATE Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 1.7 million | 4.9 million |
2023-09-30 | 1.9 million | 4.7 million |
2023-06-30 | 933000 | 4.5 million |
2023-03-31 | 59.0 million | 4.2 million |
FATE
Price: $4.22
52 week price:
Earnings Per Share: -1.64 USD
P/E Ratio: -3.92
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.6 million
Ebitda: -10.1 millionMarket Capitalization: 465.4 million